E
Enwei Pharmaceutical Co Ltd
SZSE:301331
Enwei Pharmaceutical Co Ltd
SZSE:301331
Price:
27.87
CNY
-1.1%
Market Closed
Market Cap:
¥791.3m
Income Statement
Earnings Waterfall
Enwei Pharmaceutical Co Ltd
Enwei Pharmaceutical Co Ltd
Income Statement
Enwei Pharmaceutical Co Ltd
Enwei Pharmaceutical Co Ltd
Currency: CNY
| Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
3
|
3
|
0
|
0
|
|
| Revenue |
681
N/A
|
676
-1%
|
692
+2%
|
892
+29%
|
584
-35%
|
785
+35%
|
573
-27%
|
778
+36%
|
776
0%
|
812
+5%
|
825
+2%
|
873
+6%
|
889
+2%
|
|
| Gross Profit | ||||||||||||||
| Cost of Revenue |
(323)
|
(335)
|
(344)
|
(446)
|
(286)
|
(383)
|
(290)
|
(389)
|
(389)
|
(403)
|
(422)
|
(453)
|
(465)
|
|
| Gross Profit |
358
N/A
|
342
-5%
|
347
+2%
|
447
+29%
|
298
-33%
|
402
+35%
|
284
-29%
|
389
+37%
|
387
-1%
|
409
+6%
|
403
-1%
|
420
+4%
|
423
+1%
|
|
| Operating Income | ||||||||||||||
| Operating Expenses |
(248)
|
(244)
|
(267)
|
(336)
|
(235)
|
(311)
|
(251)
|
(344)
|
(347)
|
(364)
|
(350)
|
(353)
|
(364)
|
|
| Selling, General & Administrative |
(258)
|
(253)
|
(257)
|
(332)
|
(226)
|
(288)
|
(243)
|
(334)
|
(341)
|
(329)
|
(343)
|
(347)
|
(360)
|
|
| Research & Development |
(4)
|
(5)
|
(7)
|
(9)
|
(12)
|
(16)
|
(10)
|
(12)
|
(8)
|
(8)
|
(9)
|
(8)
|
(8)
|
|
| Depreciation & Amortization |
(8)
|
0
|
(16)
|
0
|
0
|
(19)
|
0
|
0
|
0
|
(29)
|
0
|
0
|
0
|
|
| Other Operating Expenses |
21
|
15
|
12
|
6
|
3
|
12
|
2
|
2
|
2
|
3
|
2
|
2
|
3
|
|
| Operating Income |
110
N/A
|
98
-11%
|
80
-18%
|
111
+39%
|
63
-44%
|
91
+46%
|
32
-65%
|
45
+38%
|
40
-10%
|
45
+12%
|
53
+18%
|
68
+27%
|
59
-12%
|
|
| Pre-Tax Income | ||||||||||||||
| Interest Income Expense |
(0)
|
(0)
|
2
|
5
|
7
|
10
|
6
|
7
|
5
|
5
|
4
|
5
|
5
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
|
| Total Other Income |
0
|
(0)
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
(1)
|
(4)
|
(3)
|
(3)
|
(3)
|
(0)
|
|
| Pre-Tax Income |
110
N/A
|
98
-11%
|
82
-16%
|
116
+42%
|
70
-40%
|
101
+45%
|
38
-63%
|
50
+33%
|
42
-17%
|
47
+12%
|
54
+16%
|
69
+28%
|
64
-7%
|
|
| Net Income | ||||||||||||||
| Tax Provision |
(14)
|
(12)
|
(14)
|
(21)
|
(15)
|
(15)
|
(7)
|
(10)
|
(6)
|
(9)
|
(9)
|
(12)
|
(12)
|
|
| Income from Continuing Operations |
96
|
86
|
68
|
95
|
55
|
86
|
31
|
40
|
35
|
37
|
45
|
58
|
52
|
|
| Income to Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Net Income (Common) |
96
N/A
|
86
-11%
|
68
-21%
|
95
+41%
|
55
-42%
|
86
+57%
|
31
-64%
|
40
+31%
|
35
-12%
|
37
+6%
|
45
+21%
|
58
+28%
|
52
-10%
|
|
| EPS (Diluted) |
1.38
N/A
|
1.22
-12%
|
0.65
-47%
|
1.36
+109%
|
0.52
-62%
|
0.83
+60%
|
0.3
-64%
|
0.39
+30%
|
0.35
-10%
|
0.37
+6%
|
0.45
+22%
|
0.58
+29%
|
0.52
-10%
|
|
Switch to:
Switch to:
See Also
Discover More
